Morgan Stanley Gossamer Bio, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 566,419 shares of GOSS stock, worth $1.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

566,419

Previous 818,691 30.81%

Holding current value

$1.53 Million

Previous $1.01 Million 48.01%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.21 - $3.46 $305,249 - $872,861	-252,272 Reduced 30.81%	566,419 $1.49 Million
Q2 2025 Aug 15, 2025	BUY	$0.78 - $1.44 $280,143 - $517,187	359,158 Added 78.16%	818,691 $1.01 Million
Q1 2025 May 15, 2025	BUY	$0.85 - $1.53 $264,331 - $475,796	310,978 Added 209.34%	459,533 $505,000
Q4 2024 Feb 14, 2025	SELL	$0.66 - $1.07 $20,908 - $33,897	-31,680 Reduced 17.58%	148,555 $133,000
Q3 2024 May 14, 2025	SELL	$0.79 - $1.25 $11,398 - $18,036	-14,429 Reduced 7.41%	180,235 $178,000

Q3 2024 Nov 14, 2024	SELL	$0.79 - $1.25 $11,398 - $18,036	-14,429 Reduced 7.41%	180,235 $178,000
Q2 2024 May 14, 2025	BUY	$0.51 - $1.27 $23,515 - $58,558	46,109 Added 31.04%	194,664 $175,000
Q2 2024 Oct 17, 2024	SELL	$0.51 - $1.27 $2.11 Million - $5.26 Million	-4,140,436 Reduced 95.51%	194,664 $175,000
Q2 2024 Aug 14, 2024	SELL	$0.51 - $1.27 $2.11 Million - $5.26 Million	-4,140,436 Reduced 95.51%	194,664 $175,000
Q1 2024 Oct 17, 2024	BUY	$0.8 - $1.51 $3.31 Million - $6.25 Million	4,140,436 Added 2126.97%	4,335,100 $5.12 Million
Q1 2024 Aug 16, 2024	SELL	$0.8 - $1.51 $987,017 - $1.86 Million	-1,233,772 Reduced 22.15%	4,335,100 $5.12 Million
Q1 2024 May 15, 2024	SELL	$0.8 - $1.51 $987,017 - $1.86 Million	-1,233,772 Reduced 22.15%	4,335,100 $5.12 Million
Q4 2023 Aug 16, 2024	BUY	$0.48 - $1.08 $2.58 Million - $5.8 Million	5,374,208 Added 2760.76%	5,568,872 $5.07 Million
Q4 2023 Feb 13, 2024	BUY	$0.48 - $1.08 $2.49 Million - $5.59 Million	5,177,501 Added 1322.91%	5,568,872 $5.07 Million
Q3 2023 Nov 15, 2023	SELL	$0.78 - $1.82 $144,213 - $336,497	-184,889 Reduced 32.08%	391,371 $324,000
Q2 2023 Aug 14, 2023	SELL	$0.98 - $1.53 $189,679 - $296,131	-193,550 Reduced 25.14%	576,260 $691,000
Q1 2023 May 15, 2023	SELL	$0.96 - $2.92 $2.3 Million - $6.99 Million	-2,393,535 Reduced 75.66%	769,810 $969,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $12.87 $3.4 Million - $25.2 Million	1,955,742 Added 161.95%	3,163,345 $6.86 Million
Q3 2022 Nov 14, 2022	SELL	$7.21 - $14.88 $1.22 Million - $2.52 Million	-169,661 Reduced 12.32%	1,207,603 $14.5 Million
Q2 2022 Oct 27, 2022	BUY	$5.97 - $9.97 $505,712 - $844,548	84,709 Added 6.55%	1,377,264 $11.5 Million
Q2 2022 Aug 15, 2022	BUY	$5.97 - $9.97 $505,712 - $844,548	84,709 Added 6.55%	1,377,264 $11.5 Million
Q1 2022 Oct 27, 2022	SELL	$8.44 - $12.49 $714,943 - $1.06 Million	-84,709 Reduced 6.15%	1,292,555 $11.2 Million
Q1 2022 May 13, 2022	BUY	$8.44 - $12.49 $596,708 - $883,043	70,700 Added 5.79%	1,292,555 $11.2 Million
Q4 2021 Feb 14, 2022	BUY	$10.12 - $14.07 $9.8 Million - $13.6 Million	967,952 Added 381.23%	1,221,855 $13.8 Million
Q3 2021 Nov 15, 2021	BUY	$7.25 - $13.23 $1.84 Million - $3.36 Million	253,903 New	253,903 $3.19 Million

Others Institutions Holding GOSS

# of Institutions

180

Shares Held

163M

Call Options Held

8.11M

Put Options Held

211K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $255M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account